摘要
目的系统评价加替沙星治疗难治、耐多药肺结核的疗效和安全性。方法计算机检索Cochrane图书馆和PubMed、EMASE、CBM、CNKI、维普、万方数据库,按纳入排除标准选择试验,并对其进行质量评价。用RevMan5.0软件对数据进行Meta分析。结果共纳入11篇文献,Meta分析结果显示,加替沙星治疗组痰菌转阴率、病灶吸收率、空洞改变率均优于对照组(P<0.05)。结论现有的证据表明,加替沙星与一线抗结核药物联用治疗难治、耐多药肺结核的疗效优于一线抗结核药物的方案,且加替沙星可能是优于左氧氟沙星的氟喹诺酮类二线抗结核病药物,但由于纳入的文献数量有限、质量普遍不高、存在潜在的发表偏倚,有待高质量、大样本的随机双盲对照试验加以验证。
Objective To systematically assess the clinical efficacy and safety of gatifloxacin in treatment of refractory multidrug-resistant tuberculosis（MDR-TB）.Methods The related literatures were retrieved from PuMed,EMBASE,Cochrane,SCI,CBM,VIP,CNKI,WangFang databases by computer.The studies were enrolled according to including and excluding criteria,their quality was evaluated and meta-analysis was conducted by RevMan 5.0 software.Results The 11 studies of randomized controlled trails（RCTs） were included and the results of meta analysis showed that the sputum bacteria negative conversion rate,the focus absorption rate and the cavity change rate in the trial group were superior to the control group with statistical significance（P 0.5）.Conclusion The existing evidence indicates that gatifloxacin combination with first-line antituberculosis drugs has a better effect in the treatment of refractory MDR-TB than first-line antituberculosis drugs alone.Moreover,gaitfloxacin,which belongs to the second-line anti-antituberculosis drug fluoroquinolones,may be a better choice than levofloxacin.However,due to limited quantity,poor quality and potential publication bias of included literatures,the above results need to be confirmed by high quality,large sample double-blind randomized controlled trials.
出处
《中国药业》
CAS
2011年第14期17-21,共5页
China Pharmaceuticals
关键词
加替沙星
抗结核病药物
肺结核
系统评价
gatifloxacin
antituberculosis drug
pulmonary tuberculosis
systematic assessment
